NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Akebia Therapeutics, Inc. AKBA
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$236.2M
▲ 47.5% vs FY2024
EPS · FY25
$-0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-2.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 236.2M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 2 cents on every revenue dollar this year.
Per share
USD -0.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin9.9%
Net margin-2.3%
Return on assets-1.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−4.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−6.9%
−4.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.27B
Shares outstanding, FY2025
Change, 5 years+79.3%
Change, 10 years—
The share count grew 79% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 376.6M
total assets, end of FY2025
Total assetsUSD 376.6M
EquityUSD 32.6M
CashUSD 184.8M
Gross debtUSD 48.2M
Net debtUSD -136.6M
Current ratio1.55×
The company holds more cash than debt.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.2
0.2
0.2
0.3
0.2
0.3
0.3
0.2
0.2
0.0
0.0
0.0
·
·
Operating income $B
0.0
−0.1
−0.0
−0.1
−0.3
−0.4
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
0.0
−0.0
−0.0
−0.1
−0.3
−0.4
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
·
·
·
·
·
·
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.3
−0.4
−0.3
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.02
−0.33
−0.28
−0.52
−1.70
−2.78
−2.36
−2.47
−1.69
−3.60
−2.29
−8.04
−126.94
−27.82
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
−237.8
−177.2
−120.8
−54.4
−37.9
−77.3
−136.3
−51.7
·
·
·
Shares out B
0.27
0.22
0.19
0.18
0.18
0.15
0.12
0.12
0.05
0.04
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed